Compare LAES & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAES | GLUE |
|---|---|---|
| Founded | 2022 | 2019 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.0M | 308.8M |
| IPO Year | N/A | 2021 |
| Metric | LAES | GLUE |
|---|---|---|
| Price | $4.43 | $16.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 19.9M | 980.7K |
| Earning Date | 12-11-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | $10,978,000.00 | ★ $181,538,000.00 |
| Revenue This Year | N/A | $66.94 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $64.10 |
| Revenue Growth | N/A | ★ 1112.27 |
| 52 Week Low | $0.35 | $3.50 |
| 52 Week High | $11.00 | $16.66 |
| Indicator | LAES | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 44.61 | 72.97 |
| Support Level | $3.30 | $13.27 |
| Resistance Level | $4.47 | $16.66 |
| Average True Range (ATR) | 0.49 | 1.02 |
| MACD | -0.10 | 0.08 |
| Stochastic Oscillator | 37.34 | 88.50 |
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.